Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Amortization of Deferred Charges (2016 - 2017)

Bone Biologics has reported Amortization of Deferred Charges over the past 2 years, most recently at $9794.0 for Q4 2017.

  • Quarterly Amortization of Deferred Charges changed 0.02% to $9794.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $39177.0 through Dec 2017, down 28.76% year-over-year, with the annual reading at $21283.0 for FY2018, 45.67% down from the prior year.
  • Amortization of Deferred Charges was $9794.0 for Q4 2017 at Bone Biologics, roughly flat from $9795.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $25613.0 in Q1 2016 and troughed at $9793.0 in Q3 2016.